A steroid-sparing strategy: could olanzapine curb chemo nausea without the metabolic toll?

This trial tests whether olanzapine can replace dexamethasone in preventing delayed nausea and vomiting after chemotherapy in breast cancer patients who have metabolic risk factors like diabetes or obesity. Participants receive either an olanzapine-based regimen or the standard dexamethasone-containing regimen, and researchers compare how well each controls symptoms and affects blood sugar and insulin resistance. The goal is to find an equally effective anti-nausea approach with fewer metabolic side effects.